Extensive research indicates that TAMs, crucial components of the TME, significantly influence the efficacy of programmed death‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) inhibitors.[37] Consequently, we administered anti‐PD‐1 (aPD1) treatment to subcutaneous tumor‐bearing mice co‐injected with CT26 and NIH3T3 (LV‐VEC/LV‐VTN) cells (Figure7A). The gene discussed is PDCD1; the disease is neoplasm.